The mechanism that was hoped for
Early animal work suggested stem cells might replace lost neurons, or more plausibly, reduce inflammation, support surviving tissue and promote new blood vessels in the damaged area. Human trials have tested bone marrow mononuclear cells, mesenchymal stem cells, neural stem cell lines and modified cell products, delivered intravenously, intra-arterially into the carotid, or surgically into the brain.
What the major trials showed
- Intravenous bone marrow cells in acute stroke: multiple Phase 2 trials in India, Europe and the US found the infusions safe but no better than control on disability scores at three to six months
- Intra-arterial delivery: feasible, some safety concerns from microemboli, no consistent efficacy signal
- A large multinational Phase 3 of a modified bone marrow-derived product in acute ischemic stroke failed its primary endpoint; subgroup analyses hinted at benefit in patients treated within a narrow early window, prompting further study
- Surgically implanted neural cells in chronic stroke: small trials reported motor improvements in some participants, drawing attention, but were uncontrolled or small and included a surgical procedure whose own effects are hard to separate
- Chronic stroke IV MSC trials: small, mixed, with modest signals that did not reach the threshold of clinical proof
The honest summary: safety is reasonably established; efficacy is not, and the best-designed trials have been negative.
Why clinics still sell it
Stroke survivors are motivated, recovery plateaus are frustrating, and spontaneous late improvement with intensive rehabilitation gives clinics a stream of testimonials that would have happened anyway. An IV infusion of umbilical cord MSCs, the standard clinic product, has never shown benefit in a controlled stroke trial and would not be expected to reach the brain in meaningful numbers; see why route of administration matters.
Specific things to be wary of
- Intrathecal (spinal fluid) injections marketed for stroke; adds risk without evidence
- Claims of "reactivating dormant neurons"
- Packaging stem cells with hyperbaric oxygen, ozone, or "neuro-nutrient" IVs into a multi-week program
- Before-and-after videos with no timeline and no rehabilitation control
What actually improves stroke recovery
- High-intensity, high-repetition task-specific rehabilitation, well past the point insurers usually stop paying
- Constraint-induced movement therapy for eligible arm deficits
- Vagus nerve stimulation paired with rehabilitation, FDA-approved in 2021 for chronic upper-limb deficits, with L1 evidence
- Spasticity management, including botulinum toxin
- Enrollment in a registered cell therapy trial if you qualify; see finding trials
Where Colombia fits
Colombia's real value for a stroke survivor is intensive rehabilitation at a fraction of US cost. Multi-week inpatient or daily outpatient neurorehabilitation programs in Bogotá or Medellín typically cost USD 2,000 to 5,000 per month including therapy, which is often more hours of therapy than a US insurer will authorize in a year. That is an evidence-based use of a medical trip. A stem cell infusion is not; we do not refer for it. See neurological conditions in Colombia.
Regulatory status: FDA vs INVIMA
United States (FDA): The only FDA-approved stem cell products are hematopoietic (blood-forming) cell products for blood cancers and immune disorders. There is no approved stem cell therapy for stroke, cerebral palsy, brain injury, Parkinson's disease, macular degeneration or hearing loss. Legitimate access in the US is through registered clinical trials listed at ClinicalTrials.gov.
Colombia (INVIMA): Cell therapies fall under advanced-therapy regulation. Facilities need INVIMA habilitation and laboratory-processed cell products need product authorization or an approved research protocol. Verify the clinic's INVIMA status and the physician's ReTHUS registration. Neurologic indications are experimental everywhere; a Colombian clinic offering them outside a documented protocol should be treated with corresponding caution.
Frequently asked questions
Has stem cell therapy been proven for stroke?
No. Safety is established across many trials, but the largest and best-designed efficacy trials did not meet their endpoints.
Is there anything new that works for stroke recovery?
Paired vagus nerve stimulation with rehabilitation has L1 evidence for chronic arm weakness. Intensive rehabilitation remains the foundation.
Can I get intensive rehab in Colombia?
Yes. Neurorehabilitation programs in major cities offer daily therapy at roughly USD 2,000 to 5,000 per month.
Recovering from a stroke and looking abroad?
We can help you find intensive neurorehabilitation in Colombia, which the evidence supports. We will not refer you for an infusion it does not.
WhatsApp Andy in MedellínRequest a quote